Silverback Logo

News Details

Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021

11-12-2021

SEATTLE--(BUSINESS WIRE)--Nov. 12, 2021-- Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021. SBT8230 comprises a TLR8 agonist conjugated to an antibody specific to the liver-restricted receptor, ASGR1, and is designed to promote functional cures in chronic HBV (cHBV) through activation of an anti-viral immune response in a liver-localized manner.

“Our preclinical studies demonstrate that SBT8230 is efficiently delivered to the liver. This results in myeloid cell activation in liver, but not in blood. Moreover, our SBT8230 mouse surrogate was shown to reduce HBV surface antigen and drive seroconversion in an AAV-HBV mouse model consistent with the potential to generate immune responses associated with functional cures,” said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. “We look forward to initiating Phase 1-enabling toxicology studies in the first quarter of 2022.”

The poster is now available on the AASLD website and on the Silverback website here. Details are as follows:

Poster Title: SBT8230, an ASGR1-directed TLR8 ImmunoTAC therapeutic for the treatment of chronic hepatitis B virus, demonstrated favorable preclinical tolerability with liver-localized activity

Presenter: Graham Jang, PhD

Category: Hepatitis B: Therapeutics: New Agents

Publication Number: 846

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Silverback’s plans and ability to bring new treatments to patients in need, including potential combination efforts, and the progress and expected timing of Silverback’s drug development programs and clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Silverback may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties that Silverback faces, please refer to Silverback’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Silverback assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Miguel Arcinas
Silverback Therapeutics
(206) 736-7946
ir@silverbacktx.com

Media Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason.spark@canalecomm.com

 

Source: Silverback Therapeutics, Inc.

© Copyright 2021 - Silverback Therapeutics®